Intragenic deletion in the LARGE gene causes Walker-Warburg syndrome
- First Online:
- Cite this article as:
- van Reeuwijk, J., Grewal, P.K., Salih, M.A.M. et al. Hum Genet (2007) 121: 685. doi:10.1007/s00439-007-0362-y
- 563 Downloads
Intragenic homozygous deletions in the Large gene are associated with a severe neuromuscular phenotype in the myodystrophy (myd) mouse. These mutations result in a virtual lack of glycosylation of α-dystroglycan. Compound heterozygous LARGE mutations have been reported in a single human patient, manifesting with mild congenital muscular dystrophy (CMD) and severe mental retardation. These mutations are likely to retain some residual LARGE glycosyltransferase activity as indicated by residual α-dystroglycan glycosylation in patient cells. We hypothesized that more severe LARGE mutations are associated with a more severe CMD phenotype in humans. Here we report a 63-kb intragenic LARGE deletion in a family with Walker-Warburg syndrome (WWS), which is characterized by CMD, and severe structural brain and eye malformations. This finding demonstrates that LARGE gene mutations can give rise to a wide clinical spectrum, similar as for other genes that have a role in the post-translational modification of the α-dystroglycan protein.
Abnormal O-linked glycosylation of α-dystroglycan is the common pathogenic mechanism in a group of patients with a clinical spectrum ranging from severe congenital muscular dystrophy (CMD), structural brain, and eye abnormalities [Walker-Warburg syndrome (WWS), MIM 236670] to a relative mild form of limb-girdle muscular dystrophy (LGMD2I, MIM 607155) (van Reeuwijk et al. 2005a). In muscle tissue, α-dystroglycan acts as a bridge between the extracellular matrix laminin and the actin cytoskeleton through the transmembranal β-dystroglycan. The interaction of α-dystroglycan with the extracellular matrix proteins is mediated by its O-glycosylated moiety. Mature α-dystroglycan in brain binds to laminin and neurexin, which is important for neuronal migration in the neocortex and the integrity of the glia limitans (Barresi and Campbell 2006).
Mutations that result in hypoglycosylation of α-dystroglycan have been identified in known and putative glycosyltransferase genes: FCMD, FKRP, LARGE, POMGnT1, POMT1, and POMT2 (Freeze 2006). Four of these genes, FCMD, FKRP, POMT1, and POMT2, have been implicated in WWS. These genes explain approximately one-third of the WWS patients in our cohort. Interestingly, different mutations in these genes are known to cause phenotypic variability ranging from WWS to limb-girdle muscular dystrophy. Thus, it appears that mutations in genes that affect the glycosylation of α-dystroglycan can give rise to a number of related disorders, thereby blurring the boundaries between these clinically defined ‘dystroglycanopathies’ (Freeze 2006; Mercuri et al. 2006; van Reeuwijk et al. 2006; van Reeuwijk et al. 2005a). Here, we have investigated whether allelic variability does also occur for the LARGE gene.
The LARGE protein is a putative glycosyltransferase, required for addition of as yet unknown glycans onto the α-dystroglycan protein. Interestingly, overexpression of LARGE can by-pass the glycosylation defects in cells from patients with WWS or muscle-eye–brain disease (MEB, MIM 253280) (Barresi et al. 2004). Mutations in LARGE have been identified in a patient with relatively mild CMD and severe mental retardation (MDC1D: MIM 608840). This patient is compound heterozygous for p.E509K and p.C667fs. These mutations do not seem to abolish the activity of the LARGE protein completely, as Western blot analysis of skeletal muscle from this patient indicates residual functional glycosylation and laminin binding activity for α-dystroglycan (Longman et al. 2003). Interestingly, myd mice that carry a spontaneous deletion in Large (Largemyd), resemble the more severe clinical Fukuyama congenital muscular dystrophy (FCMD, MIM 253800), and MEB (Grewal et al. 2001; Longman et al. 2003; Michele et al. 2002).
Based on linkage studies we expect that there are multiple other genes that give rise to a WWS phenotype when mutated (van Reeuwijk et al. 2005b, and unpublished data). Here we report a homozygous 63-kb intragenic deletion in LARGE, in a patient who had familial classical WWS characteristics. This result establishes LARGE as the fifth WWS gene.
Patients and methods
Laboratory investigations showed remarkably high-creatine kinase (CK) of 28,600 U/l (N 24–170) on the third day of life and 1,086 U/l at the age of 1 month. Liver function tests (LFT), metabolic screen, TORCH panel for congenital infections were all normal. Chromosome analysis was normal female karyotype. Brain CT (Fig. 1b, c) showed marked dilatation of the lateral ventricles with moderate dilatation of the third ventricle, there was a striking decrease in attenuation surrounding the dilated ventricles, the inferior cerebellar vermis was absent, and the cerebellum was hypoplastic. EEG showed frequent right tempro-occipital burst of sharp and slow activity. Brain auditory evoked responses (BAER) using monoaural click stimulation was normal. Muscle biopsy showed features of dystrophy. A diagnosis of WWS was made based on the CNS, eye, and muscle involvements. No DNA or tissue sample was available for this study.
Patient 2 is the younger sibling of patient 1. Antenatal ultrasound showed hydrocephalus and he was delivered by emergency cesarean section. Apgar scores were 6 and 9 at 1 and 5 min, respectively. Physical examination (Fig. 1d) showed severe hydrocephalus with wide fontanel and separated sutures, and head circumference was 46 cm, above the 97th centile. He had generalized hypotonia, absent deep tendon reflexes but no dysmorphic features. Ophthalmic examination showed bilateral leukocornia, retinal dysplasia, and posterior synechia. Brain CT (Fig. 1e, f) revealed severe hydrocephalus with Dandy-Walker malformation and minimal brain tissue, absent inferior cerebellar vermis and hypoplastic cerebellum. CK was elevated at 18,000 U/l (N 24–195). Lactate dehydrogenase was high at 1,690 U/l (N 230–460). Liver enzymes were mildly elevated, alanine aminotransferase (ALT) 53 U/l (N 10–50), and aspartate aminotransferase (AST) 142 U/l (N 10–45 U/l). Tandem mass spectrometry (MS) for metabolic screen was unremarkable; TORCH for congenital infections was negative. Chromosome analysis showed normal male karyotype. Muscle biopsy was done at the age of 11 days and revealed dystrophic features in the form of myofiber necrosis, basophilic fibers and interstitial endomysial, and perimysial fibrosis. There was no specific fiber type atrophy or grouping. A limited number of immunostains were done and included dystrophin and α-sarcoglycan. Both immunostains were normally positive.
A ventriculoperitoneal shunt was inserted. He was weaned off the ventilatory support and died at the age of 2 months. A diagnosis of WWS was made.
Linkage analysis and mutation analysis
DNA was extracted from blood lymphocytes using standard procedures. Linkage to the LARGE locus was assessed by genotyping two microsatellite markers flanking the gene (D22S281 and D22S529) and two intragenic markers (D22S1162 and D22S1172).
Primer3 (http://www.frodo.wi.mit.edu) was used to design specific primers (supplementary Table 1) for PCR amplification and direct sequencing of the 14 coding exons (including intron–exon boundaries) of LARGE (NM_004737.3).
Copy number detection
Copy number detection of the 16 LARGE exons was performed by Multiplex Amplifiable Probe Hybridization (MAPH). A series of probes for the 16 LARGE exons were generated by PCR and cloned into pZERO (Invitrogen, Carlsbad, CA, USA). MAPH was carried out and probe ratios analyzed essentially as previously described (Armour et al. 2000; Hollox et al. 2002).
Multiplex Ligation-dependent Probe Amplification (MLPA) was used to further restrict the deletion breakpoints. MLPA probes were designed within exons 8–11 and intron 8 and 10 of the LARGE gene (supplementary Table 2). A protocol for designing these probes and hybridization, ligation, and amplification of these probes is provided by MRC-Holland (http://www.mlpa.com). Product separation was performed using capillary electrophoresis on an ABI 3730 or 3100 sequencer (Applied Biosystems, Foster City, CA). For quantitative analysis, trace data were retrieved using Genemapper software following the manufacturer’s protocol (Applied Biosystems).
Long-range PCR method and sequence analysis of breakpoints
The breakpoint-spanning region was amplified by long-range PCR amplification with specific primers (supplementary Table 3) and LA TaqTM (TaKaRa Bio Inc., Shiga, Japan) using PCR conditions recommended by the manufacturer. We then used different combinations of primers to further restrict the breakpoint-spanning region and identified the breakpoint by direct sequencing.
Linkage to the LARGE locus and mutation analysis
We hypothesized that severe LARGE mutations give rise to WWS. To assess this hypothesis we selected intragenic and LARGE flanking genetic markers to test for homozygosity in 30 WWS patients from consanguineous parents. Seven patients from six unrelated families showed homozygosity for at least two intragenic markers (D22S1162 and D22S1172) and one marker (D22S281 or D22S529) in close proximity of LARGE.
We performed mutation analysis for all 14 coding exons including intron–exon boundaries by direct sequence analysis. No mutations were found. However, difficulties during the PCR amplification of some of the exons suggested a possible deletion of these exons in one of the families. Two affected siblings in this family manifest typical WWS features as described in the patients and methods section.
Identification of a submicroscopic deletion by copy number detection
Analysis of breakpoints
We previously reported mutations in POMT1, POMT2, FCMD, and FKRP in approximately one-third of the WWS patients in our cohort (van Reeuwijk et al. 2005b). Here we report a homozygous 63-kb intragenic deletion in LARGE in a patient with WWS. The clinical features of the patients in this family do not diverge from the typical manifestations of other WWS patients. Hence, none of the five WWS genes that are known to date are associated with discriminating clinical features. The deletion described in this report is likely a loss of function mutation due to a predicted frameshift of the open reading frame within the first predicted catalytic domain. Mice carrying a similar disruptive defect in the Large gene display a severe muscle, eye, and brain phenotype, and have a shortened life span. With regard to the brain defects, these mice have severe neuronal migration defects resulting in a lissencephalic phenotype (Holzfeind et al. 2002; Lee et al. 2005; Mathews et al. 1995; Michele et al. 2002). The only previously known human LARGE mutations (p.E509K and p.C667fs) were identified in a patient with CMD, subtle structural brain abnormalities and severe mental retardation (MDC1D). The less severe clinical phenotype of this patient could be explained by residual activity of the LARGE protein. By an overlay assay, the authors demonstrated that residual α-dystroglycan present in a skeletal muscle biopsy in the patient retained laminin-binding, whereas this binding is lost in the myd mice (Holzfeind et al. 2002; Longman et al. 2003; Michele et al. 2002).
The existence of phenotypic variability for different mutations is also reported for other WWS genes. Mutations in the POMT1/2 genes were initially identified in WWS (Beltrán-Valero de Bernabé et al. 2002; van Reeuwijk et al. 2005b), but subsequently also in milder conditions including limb-girdle muscular dystrophy subtype 2K (LGMD2K, MIM 609308) (Balci et al. 2005; Mercuri et al. 2006; van Reeuwijk et al. 2006). Conversely, FKRP mutations are a common cause of LGMD, denoted subtype LGMD2I, but rare mutations are also found in severe conditions such as MEB and WWS, two similar disorders with CMD and severe brain and eye malformations (van Reeuwijk et al. 2005a). A common hypomorphic mutation in the FCMD gene causes FCMD in the Japanese population (Kobayashi et al. 1998). However, loss-of-function FCMD mutations are found in more severe conditions, including WWS (Beltrán-Valero de Bernabé et al. 2003). Finally, different mutations in POMGnT1 cause phenotypic variability within the MEB disease spectrum (Taniguchi et al. 2003; Yoshida et al. 2001).
LARGE is localized to the Golgi apparatus but the exact function of LARGE is unknown (Brockington et al. 2005; Grewal et al. 2005). It contains two putative catalytic domains, one related to a bacterial glycosyltransferase, and one related to a human glycosyltransferase (Grewal et al. 2001). In addition, LARGE interacts with the N-terminal domain of α-dystroglycan, which is essential for normal glycosylation of this protein (Kanagawa et al. 2004). Another remarkable finding is the therapeutic potential of LARGE, demonstrated by the recovery of dystroglycan processing and functioning in WWS/MEB fibroblasts by overexpression of the LARGE gene (Barresi et al. 2004).
Our finding demonstrates the existence of phenotypic variability, especially with regard to the brain, caused by different mutations in LARGE. We identified a mutation in this gene in 1 of 30 families, indicating that this gene is causal for only a small percentage of WWS patients. However, two spontaneous mouse mutants for Large, both due to intragenic deletions, have been reported in addition to the WWS patient described here (Grewal et al. 2001; Lee et al. 2005). The genomic size of LARGE may predispose this gene for genomic deletions. To exclude LARGE from genetic involvement in LGMD, or CMD with or without brain involvement it will be important to examine patients for genomic deletions in this gene.
We thank the families for contributing material for this study. This work was supported by grants from the ‘Prinses Beatrix Fonds’ and ‘Stichting Spieren voor Spieren’ (MAR02-226), and the ‘Hersenstichting Nederland’ (11F503.21). JEH thanks John Armour and Jess Tyson for advice on MAPH. JEH is a BBSRC Research Development Fellow. Funding from MDA USA, The Wellcome Trust and The BBSRC to JEH.